Given the important roles of Th17 and RORγt+ Treg cells in settings of numerous autoimmune diseases (Guo, 2016; Martinez et al., 2014; Xu et al., 2018), we speculate that the development of pharmacological strategies that can activate the IL-1β-ERK-RORγtS182 negative feedback circuit and restore Th17-RORγt+ Treg balance will provide a potential opportunity for combating T cell-mediated inflammatory diseases. Here, IL1B is linked to autoimmune disease.